To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in
the treatment of patients with ventilator-associated pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Cilastatin Cilastatin, Imipenem Drug Combination Doripenem Imipenem